An Inpatient, Placebo-Controlled Study of ALLN-346 (Engineered Urate Oxidase) in Hyperuricemic Subjects
Latest Information Update: 28 Jun 2023
Price :
$35 *
At a glance
- Drugs ALLN 346 (Primary)
- Indications Gout; Hyperuricaemia
- Focus Adverse reactions; Proof of concept
- Acronyms Study 201
- Sponsors Allena Pharmaceuticals
- 20 Jun 2023 Status changed from recruiting to completed.
- 19 Jul 2022 According to an Allena Pharmaceuticals media release, company plans to provide an update on topline safety and efficacy data that includes all 16 patients enrolled in this study during Q3 2022.
- 04 Jun 2022 Results (n=11)presented at the 23rd Annual Congress of the European League Against Rheumatism